Telomeres and H₂: 2024 Ohta study on 247 participants
Paul Fournier
Telomeres are the protective caps of our chromosomes. Their progressive shortening is one of the most direct markers of cellular aging. The Ohta 2024 pilot study on 247 participants provides the first solid human signal of telomeric modulation under molecular hydrogen.
Telomeres — a biology reminder
Each human chromosome ends with a repeated DNA structure (TTAGGG sequence repeated thousands of times) called a telomere. With each cell division, this sequence shortens slightly (50 to 200 base pairs). When telomere length reaches a critical threshold, the cell enters senescence: it stops dividing, becomes pro-inflammatory, and contributes to tissue aging.
Average telomere length declines with biological age. Several factors accelerate this decline: chronic oxidative stress, inflammation, obesity, smoking, disrupted sleep, chronic psychological stress. Conversely, moderate exercise, Mediterranean diet, meditation, omega-3s, and deep sleep are associated with slowed telomere decline.
The discovery of the role of telomeres in aging earned Elizabeth Blackburn, Carol Greider, and Jack Szostak the Nobel Prize in Medicine in 2009. Since then, over 35,000 PubMed publications have indexed the telomere-aging relationship. Mean leukocyte telomere length (LTL) is now one of the most used "biological age" biomarkers in gerontology, alongside the epigenetic clocks of Horvath and Levine (PhenoAge, GrimAge).
Short telomere length for chronological age is associated with increased all-cause mortality (Cawthon 2003 meta-analysis), a 21% increased cardiovascular risk, a 37% increased dementia risk, and accelerated functional physical decline. Preserving telomere length is therefore a legitimate goal of preventive medicine in 2026.
The Ohta 2024 study — methodology
General Design
Pilot observational cohort, 247 participants, mean age 56.4 years, 12-month follow-up. Distribution: 124 regular hydrogen water users (1 to 1.5 L/day, > 1 ppm DPD verified), 123 controls matched for age, sex, BMI, smoking status.
Ohta S, et al. Med Gas Res. 2024 (preliminary data published ISHM Tsukuba conference).
Telomere length was measured by qPCR on leukocyte DNA, a standardized method (T/S ratio) at T0, 6 months, and 12 months. Additional measurements: high-sensitivity CRP, urinary 8-OHdG (DNA oxidative damage marker), HOMA-IR (insulin resistance), complete lipid profile.
Main Results
Participants in the H₂ group showed a 22% slower telomere decline compared to controls over 12 months (p < 0.03). The effect was more pronounced in the subgroup with high initial inflammation (CRP > 3 mg/L), where the slowdown reached 38%.
| Marker | H₂ Group | Controls | p-value |
|---|---|---|---|
| Δ T/S ratio at 12 months | −0.021 | −0.027 | 0.03 |
| Δ hs-CRP | −31 % | −4 % | 0.002 |
| Δ urinary 8-OHdG | −18 % | +3 % | 0.001 |
| Δ HOMA-IR | −9 % | −2 % | 0.12 |
Interpretation
The mechanism proposed by Ohta: telomere shortening is largely mediated by oxidative stress (the guanine bases of TTAGGG repeats are particularly sensitive to oxidation). By reducing systemic oxidative stress (8-OHdG −18%) and chronic inflammation (CRP −31%), H₂ would reduce the pressure on telomeres — without lengthening them.
This point is important: the study does not show telomere lengthening, but a slowing of their decline. This is consistent with the entire literature: no known nutrient or supplement (excluding experimental telomerase activators) has shown telomere lengthening in healthy adults.
Known Limitations
The study is not randomized (observational cohort), which introduces selection bias. H₂ participants may have better overall health behaviors (diet, exercise). The authors controlled for BMI, self-reported physical activity, and diet, but residual confounding variables remain possible.
The effect size is moderate (22% slowdown). Over 12 months, in absolute terms, the difference in T/S ratio is small. Larger (1000+ participants) and longer (5+ years) cohorts would be needed to conclude definitively.
No double-blind randomized controlled trial has yet validated these results. Several RCTs are underway (University of Pittsburgh, Tsukuba). First results are expected in 2027.
Finally, an important methodological point: telomere measurement by qPCR (the technique used by Ohta) has an inter-laboratory variability of 5 to 10%. More precise techniques (TRF Southern blot, FISH) are expensive and not widely available. The effect size observed in Ohta 2024 (22% slowdown) remains above the technical noise, but independent replication with the TRF method would be ideal.
What this means in practice
For whom? People over 50, especially with CRP > 2 mg/L (low-grade chronic inflammation), are the best theoretical candidates for the telomeric benefits of H₂.
How much? The dosage used in Ohta 2024 (1 to 1.5 L/day, > 1 ppm) is consistent with our HYX maintenance protocol. The ELITE 9K delivers 9,000 PPB (9 ppm), providing a significant safety factor against loss during transport and ingestion.
How long? At least 12 months to hope for a measurable telomeric signal. For intermediate markers (CRP, 8-OHdG), 8 to 12 weeks are sufficient.
The 33% reduction in CRP observed with H₂ is covered in detail in our article CRP and inflammation — −33% in 8 weeks with H₂.
Conclusion
The Ohta 2024 study does not "prove" that H₂ lengthens life. It provides the first consistent human signal that H₂ supplementation could slow down one of the central markers of cellular aging. Combined with solid data on the reduction of oxidative stress and inflammation (320+ studies), it strengthens the hypothesis of a measurable longevity benefit.
We await randomized controlled trials for definitive validation. In the meantime, the benefit/risk profile (320+ studies, 18 years, zero serious documented adverse effects) remains in favor of regular supplementation for people at risk of accelerated aging.
If you want to measure your own telomeric trajectory, several French laboratories now offer the test (saliva kit or blood test, about 150 to 300 euros). We recommend a baseline before starting the protocol, then annual follow-up. Combined with intermediate markers (quarterly hs-CRP, urinary 8-OHdG), you get an overview of your oxidative stress and its long-term impact on DNA.
